

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/767,215	BERTIN, JOHN	
	<b>Examiner</b>	<b>Art Unit</b>	
	MINH-TAM DAVIS	1642	

All participants (applicant, applicant's representative, PTO personnel):

(1) MINH-TAM DAVIS. (3) \_\_\_\_\_.

(2) JACK BRENNAN. (4) \_\_\_\_\_.

Date of Interview: 12/15/04;02/15/05.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: \_\_\_\_\_.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Claims 1-2, 21, 25-32, 34, 37-40 are allowable. Claims 21, 25, 32, 34, 37 will be amended. The 112, first paragraph rejection of Claims 26-32, 34, 37-40 is withdrawn, because the regions of SEQ ID NO:2 responsible for binding Bcl-10 (Bcl-10 is known in the art to be a pro-apoptotic protein, see for example, specification on pages 3-4)), for activation of the transcriptional factor NF- $\kappa$ B and for stimulation of Bcl-10 phosphorylation are disclosed in the instant specification (see for example, specification p. 24).